Oral CKD-506 Lessens Symptoms, Demyelination in MS Mouse Model

Oral CKD-506 Lessens Symptoms, Demyelination in MS Mouse Model

301076

Oral CKD-506 Lessens Symptoms, Demyelination in MS Mouse Model

Chong Kun Dang (CKD) Pharmaceutical’s experimental oral therapy CKD-506 suppressed inflammation, myelin loss (demyelination), and lessened symptoms in a mouse model of multiple sclerosis (MS), a study reported. Notably, the therapy resulted in benefits generally comparable to those of Gilenya (fingolimod) in these mice. But it also eased depression-like symptoms and continued to delay symptom worsening after its use was stopped, the researchers noted. These findings suggest that CKD-506, shown to be generally safe in Phase…

You must be logged in to read/download the full post.